292 related articles for article (PubMed ID: 23550899)
1. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.
Kashyap M; Tyagi P
Expert Opin Drug Metab Toxicol; 2013 May; 9(5):617-27. PubMed ID: 23550899
[TBL] [Abstract][Full Text] [Related]
2. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
3. Mirabegron: a safety review.
Tyagi P; Tyagi V; Chancellor M
Expert Opin Drug Saf; 2011 Mar; 10(2):287-94. PubMed ID: 21142693
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
5. Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.
Angulo JC; Khullar V; Nitti VW; Siddiqui E
Actas Urol Esp; 2013; 37(10):640-51. PubMed ID: 23850394
[TBL] [Abstract][Full Text] [Related]
6. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Tyagi P; Tyagi V
IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
[TBL] [Abstract][Full Text] [Related]
7. Results of a randomized phase III trial of mirabegron in patients with overactive bladder.
Nitti VW; Auerbach S; Martin N; Calhoun A; Lee M; Herschorn S
J Urol; 2013 Apr; 189(4):1388-95. PubMed ID: 23079373
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
9. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
[TBL] [Abstract][Full Text] [Related]
10. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
11. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P
Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron: A Review in Overactive Bladder Syndrome.
Deeks ED
Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
[TBL] [Abstract][Full Text] [Related]
13. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
Chapple CR; Siddiqui E
Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
[TBL] [Abstract][Full Text] [Related]
14. Mirabegron for the treatment of overactive bladder.
Gras J
Drugs Today (Barc); 2012 Jan; 48(1):25-32. PubMed ID: 22384458
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
[TBL] [Abstract][Full Text] [Related]
18. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.
Yamaguchi O; Marui E; Igawa Y; Takeda M; Nishizawa O; Ikeda Y; Ohkawa S
Low Urin Tract Symptoms; 2015 May; 7(2):84-92. PubMed ID: 26663687
[TBL] [Abstract][Full Text] [Related]
20. Mirabegron in the treatment of overactive bladder.
Leone Roberti Maggiore U; Cardozo L; Ferrero S; Sileo F; Cola A; Del Deo F; Torella M; Colacurci N; Candiani M; Salvatore S
Expert Opin Pharmacother; 2014 Apr; 15(6):873-87. PubMed ID: 24646053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
